BrainStorm Cell Therapeutics
clinical outcomes considered as measure of efficacy | BrainStorm Cell Therapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
7 of 15
Related slides by other companies
Talkspace
SPAC
January 2021
science based approach leads to superior clinical outcome | Talkspace
23andMe
Investor Day
January 2022
polygenic scores may predict safety and efficacy is incorporating clinical into our clinical trials use of polygenic scores could enable more efficient clinical development and improve the probability of success developing drugs in genetically defined patient populations may differentiate products based on better outcomes and improved benefit risk profiles providing the right drugs to the right patients | 23andMe
DICE Therapeutics
Results
March 2023
key from phase efficacy results dice | DICE Therapeutics
Talkspace
SPAC
March 2021
company highlights | Talkspace
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights